semaglutide vs tirzepatide vs liraglutide Liraglutide, semaglutide, and delay gastric emptying and Tirzepatide vs Semaglutide: A Comprehensive

The growing popularity of GLP-1 receptor agonists, especially semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), both of which are FDA-approved for type 2 diabetes and/or obesity and, has been accompanied by considerable social media attention and discussion, from which thorough analyses of user-generated data have emerged highlighting reductions in alcohol-seeking motivation, decreased drinking behavior, and altered subjective responses to alcohol (Arillotta et al

Slower titration: Instead of increasing every 4 weeks, extending to 8 or even 12 weeks between dose increases gives the GI system more time to adapt

Whilst primarily used for epilepsy and migraine prevention, it has also been associated with appetite suppression and weight loss as a secondary effect

Jan 1 2015;55(1):e15-25